

## Financial events: agenda 2011

<b>Event</b>	<b>Date * **</b>
Q4 Full Year Sales 2010	<b>8 February 2011</b>
Annual Accounts 2010	<b>24 March 2011</b>
Q1 Sales 2011	<b>11 May 2011</b>
Q2 Sales 2011	<b>26 July 2011</b>
Half Year Results 2011	<b>31 August 2011</b>
Q3 Sales 2011	<b>9 November 2011</b>

Financial year ended 31 December

*\*Subject to modification**\*\* Press releases are distributed after the financial markets closure*

### About Stentys

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

**More information on [www.stentys.com](http://www.stentys.com)**

Contacts:

### Stentys

Stanislas Piot  
CFO  
Tel.: +33 (0)1 44 53 99 42  
[stan.p@stentys.com](mailto:stan.p@stentys.com)

### NewCap.

Investor relations & Financial Communications  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[stentys@newcap.fr](mailto:stentys@newcap.fr)

STENTYS is listed on NYSE Euronext Paris  
ISIN : FR0010949404 – STNT